Today many insulin pump manufacturers claim to be leaders in product innovation and upgradability. Some even offer "free" product upgrades. So how do you know who the real leader is, and which upgrade programs are really worthy of your trust? Ask for the facts behind the claims with these three questions:
1. How much do you dedicate to research and development?
More than 300 of our scientists, engineers, and other experts are working on new innovations like integrated systems. In fact, every year Medtronic Diabetes invests 10% of our revenues in the development of these advances. That's 250 million dollars in the last five years alone and, based on the most recent public information, 12 times the investment of other insulin pump manufacturers, like Animas.1
2. What's in your pipeline?
Medtronic Diabetes' world-leading insulin pump and continuous glucose monitoring system have been accepted and utilized by physicians for years. We're uniquely qualified to further advance this technology by integrating components, developing improved glucose sensors, and automating better insulin dosing algorithms. We are on the way to the ultimate goal in diabetes management, the artificial pancreas.
3. What progress are you making?
Our MiniMed Paradigm® REAL-Time insulin pump and continuous glucose monitoring system, the world's first system to integrate insulin pump therapy with REAL-Time continuous glucose monitoring, was approved in April 2006.
Future advances are expected to "close the loop" between glucose sensing and insulin delivery, moving closer and closer to an artificial pancreas.2
The more questions you ask, the more you realize Medtronic Diabetes is the answer.
For more information on the MiniMed Paradigm Platform of insulin pumps or the Paradigm Pathway™ Program, call 1-800 MINIMED (1-800-646-4633) x7912. If you're ready to take the next step, upgrade your MiniMed Paradigm insulin pump today.